Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts

This week, 27 April 2025:

  1. Treatment-resistant hypertension
  2. Influenza transmission
  3. Nanoplastics in human brains
  4. Malaria elimination
  5. Chikungunya vaccine

  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    April 2025
  1. PERRIER F, Ahimbisibwe A, Ghiasvand R, Rueegg CS, et al
    Physical activity and mortality in melanoma patients within the Norwegian Women and Cancer study (NOWAC).
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35430.
    PubMed     Abstract available


    March 2025
  2. VIRAZELS M, Lusque A, Brayer S, Genais M, et al
    TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFalpha clinical study.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35416.
    PubMed     Abstract available


    August 2024
  3. PERERA MM, Smit AK, Smith AL, Gallo B, et al
    Adherence to melanoma screening and surveillance skin check schedules tailored to personal risk.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35146.
    PubMed     Abstract available


    July 2024
  4. FORSCHNER A, Nanz L, Maczey-Leber Y, Amaral T, et al
    Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
    Int J Cancer. 2024 Jul 20. doi: 10.1002/ijc.35103.
    PubMed     Abstract available


  5. TURNER JA, Van Gulick RJ, Robinson WA, Mughal T, et al
    Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
    Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35087.
    PubMed     Abstract available


  6. WOHLFEIL SA, Kranzmann L, Weiss C, von Wasielewski I, et al
    Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
    Int J Cancer. 2024 Jul 8. doi: 10.1002/ijc.35078.
    PubMed     Abstract available


    June 2024
  7. BLOEM M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, et al
    Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
    Int J Cancer. 2024 Jun 24. doi: 10.1002/ijc.35060.
    PubMed     Abstract available


  8. FODA BM, Misek SA, Gallo KA, Neubig RR, et al
    Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35056.
    PubMed     Abstract available


  9. KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al
    Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
    Int J Cancer. 2024;154:2176-2188.
    PubMed     Abstract available


    April 2024
  10. FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al
    PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
    Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947.
    PubMed     Abstract available


    February 2024
  11. CHELLADURAI M, Xu D, Izraely S, Ben-Menachem S, et al
    A heterodimer of alpha and beta hemoglobin chains functions as an innate anticancer agent.
    Int J Cancer. 2024;154:561-572.
    PubMed     Abstract available


    January 2024
  12. VAN DUIN IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, et al
    A prediction model for response to immune checkpoint inhibition in advanced melanoma.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34853.
    PubMed     Abstract available


    December 2023
  13. DINTER L, Karitzky PC, Schulz A, Wurm AA, et al
    BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Int J Cancer. 2023 Dec 11. doi: 10.1002/ijc.34807.
    PubMed     Abstract available


    November 2023
  14. HUERGO-BANOS C, Velasco V, Garate J, Fernandez R, et al
    Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples.
    Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34800.
    PubMed     Abstract available


  15. TOPE P, Morais S, El-Zein M, Franco EL, et al
    Differences in site-specific cancer incidence by individual- and area-level income in Canada from 2006 to 2015.
    Int J Cancer. 2023;153:1766-1783.
    PubMed     Abstract available


    October 2023
  16. AFSHAR N, Dashti SG, Mar V, Te Marvelde L, et al
    Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data.
    Int J Cancer. 2023 Oct 12. doi: 10.1002/ijc.34752.
    PubMed     Abstract available


    September 2023
  17. ZHANG J, Zhang F, Porter KI, Dakup PP, et al
    Telomere dysfunction in Tert knockout mice delays Braf(V600E) -induced melanoma development.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34713.
    PubMed     Abstract available


    July 2023
  18. KRETSCHMER L, Bernhard L, Leha A, Kromer C, et al
    Checkpoint blockade and BRAF/MEK therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998-2009 and 2010-2017.
    Int J Cancer. 2023;153:380-388.
    PubMed     Abstract available


    June 2023
  19. FRAGALE A, Stellacci E, Romagnoli G, Licursi V, et al
    Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
    Int J Cancer. 2023 Jun 9. doi: 10.1002/ijc.34602.
    PubMed     Abstract available


    April 2023

  20. Erratum to "Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma".
    Int J Cancer. 2023 Apr 12. doi: 10.1002/ijc.34534.
    PubMed    


    February 2023
  21. VAN DUIN IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, et al
    Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34479.
    PubMed     Abstract available


  22. DE MEZA MM, Blokx WAM, Bonenkamp HJ, Blank CU, et al
    Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34485.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.